AAIC 2025 Abstract·25 DecALTITUDE‐AD: Cost Savings Using a pTau217 Screening Assay in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer's DiseaseTrial in peopleBiomarkersPaper